HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

Boston (Feb. 14, 2003) Preliminary 24-week data were presented today from the CONTEXT trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) or twice-a-day (BID) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with ritonavir (908/r) compared to a third treatment arm with the PI lopinavir/ritonavir (LPV/r, Kaletra) BID in treatment-experienced patients with prior virologic failure. The medications in all three treatment arms were administered as part of combination therapy that included two reverse transcriptase inhibitors (RTIs). In this study, 908 was administered without food or fluid restrictions.

908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX).

The primary objective of CONTEXT is to assess antiretroviral response by measuring the time averaged change in viral load (vRNA) from baseline (AAUCMB) at 24 and 48 weeks. Similar efficacy responses were seen in both the 908/r regimens and the LPV/r regimen, meeting the primary endpoint of non-inferiority in this study at 24 weeks.

"In the preliminary analysis of 24-week data, the mean AAUCMB was comparable for all three treatment arms," said Edwin DeJesus, M.D., Infectious Disease Consultants, Altamonte Springs, Fla., lead investigator on the study.

"Although these results are from only 24 weeks of study, these Phase III data on the safety and efficacy of the investigational agent 908 as therapy for HIV in PI-experienced patients with prior virologic failure are encouraging," said Doug Manion, M.D., vice president of Clinical Development, GSK.

CONTEXT is the third of three pivotal trials to support regulatory submission of 908. The 24-week CONTEXT results add to the 48-week results of the NEAT trial, also presented today in Boston, and 48-week data from the SOLO trial, presented in November 2002 at the 6th
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
(Date:10/14/2014)... sequenced the house fly genome for the first time, ... an insect that thrives in pathogen-rich dung piles and ... the journal Genome Biology , will increase understanding ... flies quickly adapt to resist insecticides, which could lead ... domestica) carry and transmit more than 100 human and ...
(Date:10/14/2014)... – Scientists from The Scripps Research Institute (TSRI) have ... Health (NIH) to lead an investigation of Lassa fever ... Africa. The study aims to understand how Lassa fever ... others survive the inflection. , "The ultimate goal ... how Lassa fever virus causes disease and develop new ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
(Date:10/22/2014)... Ras Al Khaimah, UAE (PRWEB) October 22, 2014 ... in game-changing life science and healthcare projects, announces the ... MBBS MRCGP DRCOG DCH to its advisory team. Dr. ... research advisory team. , A graduate of ... Dr. Siddiqui was subsequently degreed in medicine in 2001. ...
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: